Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. scores highest on Anchor (54) and lowest on Price (9). Its PosiPenta is 25.80 out of 100, weaker than most similar companies.
On the Penta Grid this week, Akebia Therapeutics, Inc. is Grid #805 of 837 in the Healthcare sector in United States, and Grid #3,798 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. | 25.80 | 9 | 38 | 13 | 15 | 54 |
| Neuronetics, Inc. | 37.65 | 8 | 50 | 60 | 15 | 55 |
| Coherus Oncology, Inc. | 34.71 | 24 | 50 | 25 | 19 | 56 |
| Acumen Pharmaceuticals, Inc. | 36.92 | 27 | 33 | 40 | 26 | 58 |
| Canton Strategic Holdings, Inc. | 51.30 | 48 | 73 | 18 | 71 | 47 |
| Upstream Bio, Inc. | 37.96 | 45 | 25 | 6 | 66 | 48 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -5.58 |
| P/B ratio | 7.42 |
EEarnings
| Trailing EPS | ₹-11.37 |
| Forward EPS | ₹-34.10 |
NNitro
| Price | 63.46 |
| 52-week high | 303.09 |
| 52-week low | 63.07 |
| Fall from 52-week high | 79.1% |
TTorque
| Return on equity (ROE) | -109.38% |
| Debt-to-equity | 7.96 |
AAnchor
| Beta (price swings) | 0.18 |
| Market cap | ₹1,758 Cr |
| Insider holding | 1.98% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Akebia Therapeutics, Inc.'s PosiPenta score?
Akebia Therapeutics, Inc.'s PosiPenta is 25.80 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Akebia Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Akebia Therapeutics, Inc. is Grid #805 of 837 in the Healthcare sector in United States, and Grid #3,798 of 4,000 in United States.
Which PosiPenta pillar is strongest for Akebia Therapeutics, Inc.?
Anchor (stability and dividends), with a score of 54 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Akebia Therapeutics, Inc.?
Price (valuation), with a score of 9 out of 100: much weaker than most similar companies.
Has Akebia Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.63 points, from 22.17 to 25.80.
PositoAI is for research and education only and is not investment advice.